Search Within

Joachim Yahalom

  1. "Maria Palomba"
Formats
  1. Meeting Abstract (41)
  2. Journal Article (21)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (63)
  2. Department of Medicine (63)
  3. Hematologic Malignancies, Division of (63)
  4. Lymphoma (63)
  5. Radiation Oncology, Department of (63)
  6. Survivorship Research (63)

More Groups

People
  1. Maria Palomba (63)
  2. Ariela Noy (38)
  3. Andrew Zelenetz (37)
  4. Paul Hamlin (37)
  5. Alison Moskowitz (36)
  6. Heiko Schoder (36)

More People

Years
  1. 2025 (1)
  2. 2024 (7)
  3. 2023 (13)
  4. 2022 (7)
  5. 2021 (11)
  6. 2020 (6)

More Years

Publications
  1. Blood (25)
  2. Hematological Oncology (10)
  3. Blood Advances (5)
  4. International Journal of Radiation Oncology, Biology, Physics (5)
  5. Journal of Clinical Oncology (4)
  6. Transplantation and Cellular Therapy (3)

More Publications

Publishers
  1. American Society of Hematology (30)
  2. Wiley Blackwell (10)
  3. Elsevier Inc. (8)
  4. American Society of Clinical Oncology (4)
  5. Nature Publishing Group (4)
  6. Ferrata Storti Foundation (2)

More Publishers

Results (63)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy
    Meeting Abstract

    Imber, B. S.; Palomba, M. L.; DeSelm, C.; Batlevi, C.; Dahi, P. B.; Giralt, S.; Noy, A. M.; Park, J. H.; Sauter, C. S.; Scordo, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Incidence and treatment outcomes of patients with transformed marginal zone lymphoma treated with RCHOP‐like regimens
    Meeting Abstract

    Rajeeve, S.; Bobillo, S. V.; Zelenetz, A. D.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; Moskowitz, A. J.; Hamlin, P. A.; Matasar, M. J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of stage I diffuse large B cell lymphoma (DLBCL) in the rituximab‐era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D. J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape
    Journal Article

    DeSelm, C.; Palomba, M. L.; Yahalom, J.; Hamieh, M.; Eyquem, J.; Rajasekhar, V. K.; Sadelain, M.
    Molecular Therapy (2018)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save